Vlad Coric, Biohaven CEO
Bourla called and Coric answered: Pfizer's offer for Biohaven slid $10.50 per share in under 30 days but added spinoff funds, royalties
After having secured a licensing collaboration with Pfizer for its migraine franchise outside the US in November 2021, Biohaven was on the hunt for additional …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.